at a steady clip, it will most likely want to branch out into new treatment areas. That's why a wide net approach to investment — pouring money into companies with early-stage research and high potential market caps like Semma — could be good for Vertex: Diabetes treatment cost the US healthcare systemVertex isn't the only pharma company looking at innovative approaches to drug development.
Pharma companies are exploring everything from genetics to AI in search of the next big drug development breakthrough. The current drug development pipeline is very expensive and slow, with the average treatment requiringTo try and address this pain point, pharma giant GSK spentto secure a four-year exclusive partnership to codevelop drugs based on direct-to-consumer genetic testing company 23andMe's mountains of genetic data.
, Business Insider Intelligence's expert product suite keeping you up-to-date on the people, technologies, trends, and companies shaping the future of healthcare, delivered to your inbox 6x a week. >>pass to Business Insider Intelligence and gain immediate access to Digital Health Pro, plus more than 250 other expertly researched reports.
ประเทศไทย ข่าวล่าสุด, ประเทศไทย หัวข้อข่าว
Similar News:คุณยังสามารถอ่านข่าวที่คล้ายกันนี้ซึ่งเรารวบรวมจากแหล่งข่าวอื่น ๆ ได้
แหล่ง: billboard - 🏆 112. / 63 อ่านเพิ่มเติม »